
CAPA & Deviations
Deviations, nonconformances, and complaints in one risk-based process with evidence-backed closure.
ExploreThe regulated process for investigating quality issues, removing their causes, and preventing recurrence across a QMS.
CAPA is the backbone of quality governance. A well-run CAPA program shows inspectors that your organization does not just fix issues — it understands why they happened and prevents them from returning.

CAPA stands for Corrective Action and Preventive Action. It is the regulated quality process for responding to deviations, nonconformances, audit findings, customer complaints, and other quality issues in a structured, documented, and verifiable way.
A CAPA record captures the problem, the investigation, the root cause, the actions taken to correct it (corrective action) and to prevent recurrence (preventive action), and an effectiveness check that confirms the fix worked.
CAPA is one of the most-inspected areas of any regulated quality system. FDA, EMA, MHRA, and notified bodies all look at CAPA records as primary evidence of a functioning quality culture.
A weak CAPA program — missing root causes, repeat deviations, late actions, missing effectiveness checks — is one of the top reasons regulatory bodies issue 483s, warning letters, and notified body findings.
Did you find the true root cause? Did your actions remove that cause? Did you verify the cause is actually gone?
CAPA requirements appear across most GxP regulations and standards:
A typical CAPA record moves through these stages:
Inspection-ready CAPA programs share common control patterns:
The Complere CAPA & Deviations module provides a controlled CAPA lifecycle with structured root cause capture, action plan tracking, and mandatory effectiveness checks.
Common questions about CAPA (Corrective and Preventive Action) sourced from regulatory references and inspection patterns.
An effective CAPA program captures meaningful signals, investigates root causes, documents proportional actions, and verifies effectiveness to prevent recurrence.
CAPA connects deviations to root cause analysis, documented action plans, verification activities, and cross-functional oversight rather than just recording events.
FDA 21 CFR 211, 21 CFR 820, EU GMP Chapter 1, and ICH Q10 expect documented CAPA governance with verification.
Inspectors review signal validity, root cause rationale, proportional actions, verification data, and whether the CAPA links to deviations, complaints, and management review.
Complere links CAPA findings to deviations, change control, document proofs, and audit trails, so inspectors see the full investigation-to-action story without manual compilations.
Explore related topics, modules, and compliance resources for a deeper understanding of your quality system.

Deviations, nonconformances, and complaints in one risk-based process with evidence-backed closure.
Explore
Structured fields for event intake, root cause, CAPA planning, and effectiveness review.
Explore
The buttons in your eQMS did not change on 2 February 2026 — the evidence behind them did.
Explore
Barr limits on retesting, Phase I/II under the May 2022 Level 2 revision, and the records investigators pull.
Explore
The five seams where the deviation→CAPA→change chain breaks, what an investigator traces backwards, and a seven-question linkage test.
Explore
CAPA is a Q10 element, not a module you buy. If follow-up still lives in a tracker, the QMS never moved.
Explore
How many open CAPAs name retraining as the action, and how many of those checks are only a second signature?
Explore
A CAPA closure is stronger when the trigger, action, change, training, and effectiveness evidence remain one path.
Explore
§820.100(a) CAPA procedures was the most-cited device row of FY 2025 (279); §211.192 investigations the second for drugs. The record that answers each.
Explore
§211.192 investigations added 63 citations between FY 2024 and FY 2025, more than any other drug section; what the letter then asks for.
Explore
The cycle-time data says the wasted days sit at the seams between modules, not with QA — and the seam is where the trail goes silent.
Explore
FDA's first cGMP letter to cite AI names two clauses and one accountability boundary — read backward, the clauses are a record schema.
Explore
Sponsor tagging is a metadata field, not segregation — the SQL probe, the eight auditor requests and the records a sponsor audit asks for.
Explore
Six predictable CMC and quality gaps that turn a strong first IND into a clinical hold — and where each closes cheaply before the pre-IND meeting.
Explore
Five seams where CDMO quality systems break between shared infrastructure and the sponsor-facing record — and the architecture that closes them.
Explore
Fifteen working days, a citation written against Part 820 as amended, and the CAPA records the response now has to attach.
Explore
Subjectivity named, formality made a spectrum, supply risk in scope — what the 2023 revision asks of a risk register.
Explore
Supplier quality management is one decision made repeatedly. What it has to produce, what spreadsheets and email cost, and what to demand from an eQMS.
ExploreWalk through real CAPA investigations — root cause capture, action plans, effectiveness checks — connected to deviations, audits, and change control.